Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with a primary focus in oncology and hematology, marked its ten-year anniversary in business. The milestone is being celebrated by employees in the U.S. and a growing number of locations abroad as Spectrum expands its worldwide presence. Spectrum is headquartered in Henderson, Nevada, with its Research & Development facility located in Irvine, CA; additional locations include Spectrum Pharma Canada and the Company’s subsidiary, OncoRx, in Mumbai, India. Plans include establishing and expanding offices in Japan and in Europe to support international operations.
“Spectrum has dramatically transformed itself over the past decade from a start-up company with no approved products to a dynamic industry leader with two approved drugs, substantial R&D opportunities and a successful commercial infrastructure,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals who has led Spectrum from its inception. “Our mission and passion always have been to deliver better options for patients with cancer, and we are dedicated to building on our successes over the last decade as we look toward the future. Our commitment to our patients, our people and our investors helps explain why the company has continued to receive a number of merit awards, including One of the Best Companies to Work For in Orange County and One of the Fastest Growing Companies in North America. Further, our drugs have been featured in top medical conferences in the U.S. and abroad, as well as in multiple, major peer-reviewed publications. With a growing presence in the US, we are seeking to add more commercial products, build our pipeline with new products in development, expand our global presence, and continue to create a workplace that rewards excellence and is an exciting place to work. Based on these and other strong assets, we believe we are in a formidable position to continue the same growth pace over the next decade.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts